Recent Company News

• 09:21 AM ET Oct 21, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:14 AM ET Oct 21, 2025
  

  Genmab commences tender offer for all outstanding common shares of Merus N.V. ($30.54, 0.00)

• 04:35 AM ET Oct 20, 2025
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 05:53 PM ET Oct 20, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:58 AM ET Oct 20, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 11:38 AM ET Oct 19, 2025
  

  Johnson & Johnson announces results from OrigAMI-4 study of SC amivantamab at ESMO ($193.22, 0.00)

• 06:16 AM ET Oct 18, 2025
  

  Genmab presents updated data from RAINFOL-01 trial of Rina-S at ESMO (DKK 2095.00, 0.00)

• 08:06 AM ET Oct 16, 2025
  

  Johnson & Johnson's investigational Phase 3 MajesTEC-3 study meets primary endpoint ($191.17, 0.00)

• 06:28 AM ET Oct 14, 2025
  

  Genmab reports Q3 net sales of DARZALEX $3.67B (DKK 2097.00, +20.00)